Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2017 | Treatment methods in mantle cell lymphoma

Stephen Robinson • 26 Mar 2017
EBMT 2017
Mantle Cell Lymphoma

Dr. Stephen Robinson of the Bristol Hematology Oncology Centre discusses the treatment methods involved in mantle cell lymphoma (MCL). MCL is a type of non-Hodgkin lymphoma with a relatively poor prognosis. The first-line treatment in response to MCL is an autologous transplant, other treatments include allogeneic transplantation however, there is no definitive treatment plan. A large retrospective study with EBMT was carried out to investigate the efficacy of allogeneic transplantation in MCL and results suggest that it should not be used as a first-line treatment due to evidence of association with significant toxicity. Recorded at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation

More from Stephen Robinson

1:15
CAR T-cells in hematological malignancies
Stephen Robinson • 14 Apr 2018
1:11
Hodgkin lymphoma: when autologous transplant is unsuccessful
Stephen Robinson • 14 Apr 2018
2:30
The future of CAR T-cell therapy
Stephen Robinson • 14 Apr 2018
2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson • 26 Mar 2017

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals